CRP and COVID-19: Although no studies have been reported to support the results of using siltuximab for COVID‐19, a nonpeer‐reviewed observational report from Italy suggests that siltuximab (11 mg/kg) administration was well tolerated and reduced CRP and mortality in patients.349